Health Condition 1: C851- Unspecified B-cell lymphoma
Conditions
Sponsors
Investigator initiated trial
Eligibility
Inclusion criteria
Inclusion criteria: Inclusion Criteria 1. Newly diagnosed cases of Diffuse Large B cell Lymphoma 2. Age more than or equal to 60 years. 3. Patients who provide written informed consent
Exclusion criteria
Exclusion criteria: 1. None The patients found to meet all inclusion criteria of the study will thereafter be administered the informed consent process
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of participants achieving complete response and partial response in clinical trial eligible and clinical trial ineligible cohort receiving RCHOP, will be measured.Timepoint: 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Survival analysis will be calculated from the date of enrolment till the end of 1 year, data will be censored in case the patient is lost to follow-up. Timepoint: after completion of one year treatment;Comparison of dose modifications in all the treatment cohortsTimepoint: during the treatment;Comparison of grade III and grade IV toxicities in all treatment cohorts:Timepoint: during the treatment;Proportion of patients achieving complete and partial response in clinical trial ineligible and in clinical trial eligible cohort receiving RCEOP regimen.Timepoint: after completion of treatment;Proportion of patients in the clinical trial eligible cohort.Timepoint: after the enrollment | — |
Countries
India
Contacts
Public ContactDr Hasmukh Jain
Tata Memorial Centre
Outcome results
None listed